Adaptive Biotechnologies outperformed expectations in its second quarter with revenues increasing 36 percent year-over-year to $58.9 million, driven primarily by expansion in its minimal residual disease (MRD) testing business. The MRD segment accounted for 85 percent of revenues, reflecting strong adoption of its ClonoSeq assay across clinical and pharmaceutical sectors. The company reported a net loss reduction, improved ASPs, and ongoing contract gains. These results highlight the company's growing market presence in immune medicine and precision diagnostics amid a competitive biotech landscape.